Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Feb 1, 2025 | (Q4)Feb 1, 2025 | (Q3)Nov 2, 2024 | (Q2)Aug 3, 2024 | (Q1)May 4, 2024 | (FY)Feb 3, 2024 | (Q4)Feb 3, 2024 | (Q3)Oct 28, 2023 | (Q2)Jul 29, 2023 | (Q1)Apr 29, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.04%2.27B | 2.79%667.08M | 7.79%517.43M | 12.41%578.38M | 10.82%508.82M | 15.09%2.1B | 18.04%648.95M | 14.82%480.05M | 13.71%514.51M | 12.91%459.15M |
Operating revenue | 8.04%2.27B | 2.79%667.08M | 7.79%517.43M | 12.41%578.38M | 10.82%508.82M | 15.09%2.1B | 18.04%648.95M | 14.82%480.05M | 13.71%514.51M | 12.91%459.15M |
Cost of revenue | 6.85%1.36B | 2.47%395.48M | 5.96%302.97M | 13.06%359.34M | 6.73%299.46M | 8.49%1.27B | 12.42%385.95M | 12.84%285.94M | 2.90%317.83M | 5.74%280.58M |
Gross profit | 9.86%914.45M | 3.27%271.6M | 10.48%214.46M | 11.36%219.03M | 17.24%209.36M | 26.87%832.37M | 27.37%263M | 17.87%194.11M | 36.96%196.68M | 26.35%178.57M |
Operating expense | 9.99%664.95M | 11.21%183.88M | 9.61%169.94M | 9.80%158.27M | 9.16%152.86M | 15.12%604.57M | 19.14%165.35M | 14.72%155.04M | 13.44%144.15M | 12.77%140.03M |
Selling and administrative expenses | 8.84%612.41M | 8.81%169.85M | 9.02%154.47M | 8.21%145.67M | 9.33%142.42M | 14.70%562.67M | 19.14%156.1M | 13.52%141.68M | 13.64%134.62M | 12.04%130.27M |
Depreciation amortization depletion | 19.43%33.22M | 20.90%9.21M | 17.42%8.3M | 20.27%8M | 19.02%7.72M | 21.44%27.82M | 22.66%7.62M | 20.32%7.07M | 19.29%6.66M | 23.56%6.48M |
-Depreciation and amortization | 19.43%33.22M | 20.90%9.21M | 17.42%8.3M | 20.27%8M | 19.02%7.72M | 21.44%27.82M | 22.66%7.62M | 20.32%7.07M | 19.29%6.66M | 23.56%6.48M |
Other operating expenses | 37.26%19.32M | 195.59%4.82M | 14.00%7.17M | 60.16%4.6M | -16.92%2.73M | 20.30%14.08M | 4.75%1.63M | 41.04%6.29M | -5.00%2.87M | 23.35%3.28M |
Operating profit | 9.53%249.5M | -10.17%87.73M | 13.96%44.52M | 15.65%60.76M | 46.60%56.5M | 74.00%227.8M | 44.25%97.65M | 32.29%39.07M | 217.54%52.54M | 124.78%38.54M |
Net non-operating interest income expense | 11.06%16.31M | -12.48%4.05M | 1.28%4.03M | 15.46%3.93M | 60.79%4.3M | 395.31%14.69M | 122.16%4.63M | 359.24%3.98M | 2,665.85%3.4M | 2,554.13%2.68M |
Non-operating interest income | 11.06%16.31M | -12.48%4.05M | 1.28%4.03M | 15.46%3.93M | 60.79%4.3M | 395.31%14.69M | 122.16%4.63M | 359.24%3.98M | 2,665.85%3.4M | --2.68M |
Other net income (expense) | ||||||||||
Income before tax | 9.62%265.81M | -10.27%91.78M | 12.79%48.55M | 15.64%64.69M | 47.52%60.8M | 81.12%242.49M | 46.58%102.29M | 41.61%43.05M | 235.61%55.94M | 141.92%41.21M |
Income tax | 8.20%66.05M | -10.02%23.23M | 12.66%12.67M | 14.15%15.71M | 41.25%14.46M | 96.33%61.05M | 54.62%25.81M | 53.68%11.24M | 435.12%13.76M | 126.77%10.23M |
Net income | 10.10%199.76M | -10.36%68.55M | 12.83%35.88M | 16.12%48.98M | 49.59%46.34M | 76.51%181.44M | 44.05%76.48M | 37.78%31.8M | 199.22%42.18M | 147.38%30.98M |
Net income continuous Operations | 10.10%199.76M | -10.36%68.55M | 12.83%35.88M | 16.12%48.98M | 49.59%46.34M | 76.51%181.44M | 44.05%76.48M | 37.78%31.8M | 199.22%42.18M | 147.38%30.98M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 10.10%199.76M | -10.36%68.55M | 12.83%35.88M | 16.12%48.98M | 49.59%46.34M | 76.51%181.44M | 44.05%76.48M | 37.78%31.8M | 199.22%42.18M | 147.38%30.98M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 10.10%199.76M | -10.36%68.55M | 12.83%35.88M | 16.12%48.98M | 49.59%46.34M | 76.51%181.44M | 44.05%76.48M | 37.78%31.8M | 199.22%42.18M | 147.38%30.98M |
Basic earnings per share | 10.88%3.26 | -9.68%1.12 | 13.46%0.59 | 17.65%0.8 | 52.00%0.76 | 79.27%2.94 | 45.88%1.24 | 40.54%0.52 | 195.65%0.68 | 150.00%0.5 |
Diluted earnings per share | 10.62%3.23 | -9.76%1.11 | 13.73%0.58 | 16.18%0.79 | 50.00%0.75 | 78.05%2.92 | 44.71%1.23 | 37.84%0.51 | 209.09%0.68 | 150.00%0.5 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |